Saredutant

DB06660InvestigationalSmall molecule

Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

Mechanism: Saredutant works by blocking the effects of Neurokinin A at the NK-2 receptor.
Curator reviewed
Primary indication: Investigated for use/treatment in depression and anxiety disorders.Curator reviewed
Formula / weight: C₃₁H₃₅Cl₂N₃O₂ · 552.54 g/mol (avg)
Code names: SR 48968

Resolves to

Compound

Structure

InChIKeyPGKXDIMONUAMFR-AREMUKBSSA-NSMILESCN(C[C@@H](CCN1CCC(CC1)(NC(C)=O)C1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1)C(=O)C1=CC=CC=C1

Targets

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

679Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Saredutant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.